Robust Determination of the Optimal Continuous Glucose Monitoring Length of Intervention to Evaluate Long-Term Glycemic Control
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective: Consensus continuous glucose monitoring (CGM) guidance includes a recommendation that a minimum of 14 days of CGM data are used to report times in ranges. The previously employed approaches to determine the optimal duration for CGM data have limitations. In this study, we present a robust approach to define the minimum duration of CGM data to report times in ranges, as well as other glycemic metrics. Methods: The approach is based on the median absolute percentage error and employs a sliding time window to reduce the impact of inter-time interval variability, hence allowing smaller data sets to be used. A 10% and 5% threshold were employed to assess the optimal duration of CGM data for a set of commonly employed metrics to assess quality of glycemic control and glycemic variability. To evaluate the impact of the data set size and type of intervention, data from two randomized controlled trials involving participants with type 1 diabetes were used ( n = 236 and n = 25). Results: Results suggest that mean glucose reaches the 5% threshold for mean absolute percentage error within 2 weeks, whereas percentage time in target 70–180 mg/dL, mean absolute glucose, standard deviation, and coefficient of variation reach the same threshold within 4 weeks in both data sets, suggesting that these metrics can be robustly assessed from CGM data for a 4-week period, whereas some other metrics require much longer window lengths, especially those evaluating hypoglycemia. Conclusions: Our data suggest that there is no optimal duration for CGM data to robustly assess all outcomes and that the duration required for a robust outcome depends on the population being studied, the sampling frequency, and the primary outcomes selected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“These results support the consensus metrics for CGM analysis 2,3 and are consistent with an analysis suggesting that MAG was the most discriminant metric for glycemic variability and that time in range 70–180 mg/dL was the most robust target range metric.”
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 2×
“These results support the consensus metrics for CGM analysis 2,3 and are consistent with an analysis suggesting that MAG was the most discriminant metric for glycemic variability and that time in range 70–180 mg/dL was the most robust target range metric.”
Heinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
Aleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329
Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring
Xing, D., Kollman, C., Beck, R. W., Tamborlane, W. V., Laffel, L., Buckingham, B. A., Wilson, D. M., Weinzimer, S., Fiallo-Scharer, R., & Ruedy for the Juvenile Diabetes Research Foundation Continuo, K. J. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0156 · Cited by 131
Cited by
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Jacobs, P. G., Herrero, P., Facchinetti, A., Vehi, J., Kovatchev, B., Breton, M. D., Cinar, A., Nikita, K. S., Doyle, F. J., Bondia, J., et al. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2023.3331297 · Cited by 113
Self-citationBeyond A1C: exploring continuous glucose monitoring metrics in managing diabetes
Friedman, J. G., Coyne, K., Aleppo, G., & Szmuilowicz, E. D. (2023) · Endocrine Connections · doi:10.1530/ec-23-0085 · Cited by 22
Metadata
- Authors
- Herrero, P., Alalitei, A., Reddy, M., Georgiou, P., & Oliver, N.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2021-04-01
- Volume
- 23
- Issue
- 4
- Pages
- 314-319
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W3040789068
- Cited by
- 43
- References
- 5
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Robust Determination of the Optimal Continuous Glucose Monitoring Length of Intervention to Evaluate Long-Term Glycemic Control. https://app.cochat.ai/papers/10.1089/dia.2020.0387
- The paper
- Herrero, P., Alalitei, A., Reddy, M., Georgiou, P., & Oliver, N. (2021). Robust Determination of the Optimal Continuous Glucose Monitoring Length of Intervention to Evaluate Long-Term Glycemic Control. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2020.0387
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.